Corcept Therapeutics Incorporated
CORT
Classificação em ações
#1760
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Preço da ação
$112.72
Última sincronização: 2026-10-19
Valor de mercado
$12.18B
Variação (1 dia)
2.32%
Variação (1 ano)
43.41%
País
US
Negociar Corcept Therapeutics Incorporated (CORT)
Categoria
Healthcare
Rácio P/B de Corcept Therapeutics Incorporated (CORT)
Rácio P/B em October 2026 TTM: 17.35
De acordo com os relatórios financeiros mais recentes e o preço das ações da Corcept Therapeutics Incorporated, o rácio P/B atual (TTM) é 17.35. No final de 2023, o rácio P/B era 6.64.
Histórico do rácio P/B da Corcept Therapeutics Incorporated de 2001 a 2026
Rácio P/B no final de cada ano
| Ano | Rácio P/B | Alterar |
|---|---|---|
| 2026 (TTM) | 17.35 | 126.85% |
| 2024 | 7.65 | 15.31% |
| 2023 | 6.64 | 53.60% |
| 2022 | 4.32 | -29.07% |
| 2021 | 6.09 | 5.62% |
| 2020 | 5.77 | 54.77% |
| 2019 | 3.73 | -38.76% |
| 2018 | 6.09 | -43.31% |
| 2017 | 10.74 | -44.66% |
| 2016 | 19.40 | -32.53% |
| 2015 | 28.75 | -132.16% |
| 2014 | -89.41 | -686.49% |
| 2013 | 15.25 | 608.08% |
| 2012 | 2.15 | -73.70% |
| 2011 | 8.19 | -34.07% |
| 2010 | 12.42 | 88.15% |
| 2009 | 6.60 | 134.13% |
| 2008 | 2.82 | -60.76% |
| 2007 | 7.18 | 62.61% |
| 2006 | 4.42 | 42.36% |
| 2005 | 3.10 | 23.71% |
| 2004 | 2.51 | -75.71% |
| 2003 | 10.33 | -375.72% |
| 2002 | -3.75 | -227.48% |
| 2001 | 2.94 | 0.00% |
Rácio P/B de empresas semelhantes ou concorrentes
| Empresa | Rácio P/B | Diferença do rácio P/B | País |
|---|---|---|---|
| 3.8424 | -77.86% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 2.4753 | -85.74% |
HK
|
